linjc16/ctgov huggingface dataset:
Trial of Zinc and HIV Progression in Children

Study Overview
=================
Brief Summary
-----------------
To examine whether daily oral zinc supplementation to HIV-infected Tanzanian preschool children reduces diarrheal and respiratory morbidity, delays HIV disease progression, and improves growth.

Detailed Description
-----------------
The purpose of this study is to examine whether daily oral zinc supplementation to HIV-infected Tanzanian preschool children reduces diarrheal and respiratory morbidity, delays HIV disease progression, and improves growth.

Official Title
-----------------
Trial of Zinc and HIV Progression in Children

Conditions
-----------------
HIV Infections

Intervention / Treatment
-----------------
* Dietary Supplement: Zinc


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: HIV Infected Children under 60 months of age presenting at HIV treatment clinics in Dar es Salaam, Tanzania Exclusion Criteria: Eligible for ART: CD4 cell counts < 20% or above pediatric clinical stage of HIV disease 3 according to WHO staging system. Severe acute malnutrition; Major congenital malformations

Ages Eligible for Study
-----------------
Minimum Age: 6 Weeks
Maximum Age: 60 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Zinc<br>zinc (as zinc sulphate) 12.5 mg orally per day (6.25 mg in children < 12 mo) | Dietary Supplement: Zinc<br>* zinc effervescent tablets: 6.25mg to infants ≤12 months and 12.5 mg to children > 12 months.<br>|
| Placebo Comparator: Placebo<br> | Dietary Supplement: Zinc<br>* zinc effervescent tablets: 6.25mg to infants ≤12 months and 12.5 mg to children > 12 months.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Morbidity from respiratory and diarrheal infections, HIV disease progression |  | every 4 to 6 months until the end of follow-up | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| growth in height and weight |  | every 4 to 6 months until the end of follow-up | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HIV, Morbidity, Zinc, Infants, Children, Child health outcomes, treatment naive, treatment experienced
Follow-up of Coronary Artery Bypass Graft Patency by Multislice Computed Tomography

Study Overview
=================
Brief Summary
-----------------
Coronary artery disease is a major cause of morbidity and mortality across the world and coronary artery bypass surgery (CABG) is the most common surgical procedure for treatment. Patients with recurrent ischemic symptoms after CABG are most likely to have occluded or significantly stenosis in grafts or native coronary arteries. Therefore, there is a need to evaluate the patency of these vessel conduits after CABG. Until now, selective coronary angiography is the traditional gold standard for the assessment of both native coronary arteries and bypass grafts. But it is an invasive procedure that requires x-ray exposure, hospitalization, and includes a risk for complication. However, there is an alternative noninvasive method, multislice computed tomography (MSCT), with high specificity and excellent sensitivity for the detection of the coronary artery disease. It is even cheaper and takes shorter time to perform. Accordingly, the purpose of this study is to use MSCT to evaluate the patency and the quality of all grafts and native coronary arteries after CABG for more than two years. In addition, we will elucidate the relationship of these data and CABG procedures to review our experience.

Official Title
-----------------
Follow-up of Coronary Artery Bypass Graft Patency by Multislice Computed Tomography

Conditions
-----------------
Coronary Artery Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients underwent CABG and performed MSCT after the surgeries Exclusion Criteria: Nil
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
multislice computed tomography, coronary artery bypass grafting, Patients, underwent, surgeries
Clinical Experimental Study to Investigate Specific Features of ClampArt®

Study Overview
=================
Brief Summary
-----------------
A single centre, clinical experimental study. Every subject will undergo clamp experiments, where a clamp device (ClampArt®) measures and controls the blood glucose concentration after administration of marketed insulin products.

Official Title
-----------------
Clinical Experimental Study 2, to Further Investigate the Measurement Accuracy, Glucose Control Quality, Safety, Handling and Functionality of ClampArt® and Its Influence on Pharmacodynamic Parameters in Glucose Clamps

Conditions
-----------------
Diabetes Mellitus

Intervention / Treatment
-----------------
* Device: ClampArt


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy, TD1, TD2 Exclusion Criteria: Participation in a Trial within the last weeks

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: ClampArt<br>ClampArt | Device: ClampArt<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measurement accuracy, glucose control quality, safety, handling and functionality of ClampArt® |  | up to 1 year |
Cognitive and Emotional Processing of Social Stimuli in Children and Youth With Autism Spectrum Disorder

Study Overview
=================
Brief Summary
-----------------
Children and youth diagnosed with autism spectrum disorder (ASD) have been shown to react abnormally to social stimuli, especially to human faces. Children and youth with ASD show less interest in social stimuli, and may even avoid looking at or interact with such stimuli. It has been proposed that social stimuli elicit reactions like fear and stress in individuals with ASD, and this explains the lack of interest and avoidance. The present project investigates this hypothesis.

Official Title
-----------------
Cognitive and Emotional Processing of Social Stimuli in Children and Youth With Autism Spectrum Disorder

Conditions
-----------------
Autism Spectrum Disorder

Intervention / Treatment
-----------------
* Behavioral: Pictures
* Behavioral: Startle eliciting noise


Participation Criteria
=================
Eligibility Criteria
-----------------
For ASD group: Inclusion Criteria: Diagnosed with autism spectrum disorders

Ages Eligible for Study
-----------------
Minimum Age: 7 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Normal controls<br>Normal children and youths | Behavioral: Pictures<br>* The participants will be exposed to pictures of faces and non-facial stimuli presented on a PC screen.<br>Behavioral: Startle eliciting noise<br>* Startle will be elicited by 95 dB noise, presented at different times after picture onset.<br>|
| Experimental: ASD<br>Children and youths diagnosed with autism spectrum disorder (ASD) | Behavioral: Pictures<br>* The participants will be exposed to pictures of faces and non-facial stimuli presented on a PC screen.<br>Behavioral: Startle eliciting noise<br>* Startle will be elicited by 95 dB noise, presented at different times after picture onset.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The eyeblink of the Startle reflex is measured. | The startle reflex is potentiated when participants are influenced by negative emotions. Accordingly, startle will be measured in relation to picture presentation to gauge the emotional effect of the pictures. It is expected that the ASD group will show fear potentiated startle to pictures of human faces. | The startle reflex will be measured in relation to picture presentations during the experiment (e.g. day 1). | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ASD, Startle
An Infraclavicular Landmark-based Approach to the Axillary Vein

Study Overview
=================
Brief Summary
-----------------
The central line placement is the widespread procedure performed in the intensive care and emergency medicine. Indications for this procedure are chiefly lack of peripheral catheters, administration some medications, renal replacement therapy, parenteral nutrition and hemodynamic monitoring. The procedure is performed by percutaneous puncture of large vein of the neck and the thorax - internal jugular vein or subclavian vein, then insertion of guidewire through the needle and placement of the catheter over the guidewire. The tip of the catheter is situated in the superior vena cava. There are two techniques of catheterizations: landmark-based and ultrasound-guided. The most frequently cannulated veins in landmark-based approach are internal jugular and subclavian vein. The cannulation of the axillary vein is not common procedure in the intensive care unit, mainly due its complicated original technique. The primary intention of this study was to describe and assess usefulness and safety of the new landmark-based technique of catheterization of the axillary vein in patients admitted to the intensive care unit.

Official Title
-----------------
A New Infraclavicular Landmark-based Approach to the Axillary Vein as an Alternative Method of Central Venous Cannulation

Conditions
-----------------
Critical Illness

Intervention / Treatment
-----------------
* Procedure: Catheterization of the axillary vein.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients admitted to the intensive care unit with indications for central venous catheterization Exclusion Criteria: chest wall deformities at the cannulations side major hemostasis disorders infections at the catheterization site age less than 18 years lack of patients consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: axillary vein catheterization<br>Catheterization of the axillary vein based on anatomical landmark. | Procedure: Catheterization of the axillary vein.<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of successful catheterizations. |  | 24 hours | 
| Procedure success rate depending on physician experience. |  | 24 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of early complications. |  | 24 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
critical care, catheterization, axillary vein
Effect of Sinovac on Survival in Intensive Care Unit

Study Overview
=================
Brief Summary
-----------------
Effect of Inactivated COVID-19 Vaccine (Sinovac) on survival in intensive care unit, Single Center Experience

Detailed Description
-----------------
Turkey has started vaccinate healthcare professionals at 13 January 2021 by Sinovac vaccine and declared a step by step inclusion schedule The primary aim of the study is to compare clinical, laboratory and survival data of COVID-19 patients who were vaccinated at least 14 days before enrollment to the study with COVID-19 patients not vaccinated although they would have. The secondary aim is to compare age of enrolled patients to ICU due to SARS-CoV-2 infection with patients admitted to ICU before start of vaccination program.

Official Title
-----------------
Effect of Inactivated COVID-19 Vaccine, Sinovac on Survival in Intensive Care Unit

Conditions
-----------------
Intensive Care Unit, Survival

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with covid 19 over the age of 65 who were admitted to the intensive care unit between 1 April 2021 and 15 May 2021 Exclusion Criteria: admissions to ICU due to reasons other than COVID-19, age younger than 65, continued admission at the end of enrolment date,

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Vaccinated with sinovac<br>Vaccinated COVID-19 patients over 65 years consisted the study group | |
| Unvaccinated<br>Unvaccinated patients over 65 years composed the control group | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| survival data | If the patient dies, we have reached an outcome | 30 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
sinovac, covid-19 vaccine
Adipose Inflammation and Diabetes (FAB)

Study Overview
=================
Brief Summary
-----------------
The study investigates whether the addition of resolution molecules can inhibit inflammation and insulin resistance in human tissue taken from obese individuals, and whether the results of these studies correlate with patient-specific resolution phenotypes.

Official Title
-----------------
Adipose Tissue Inflammation and Diabetes Development (Fettvävsinflammation Och Diabetesutveckling)

Conditions
-----------------
Obese

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: BMI 30-40 kg/m2 Ptos (i.e. excess skin) > 3 cm Patient underwent gastric bypass surgery >2 years ago Patient has had a stable weight ≥6 months at the time of operation Patient does not smoke (min 6 weeks prior to surgery) Exclusion Criteria: Patients who do not understand spoken and written Swedish American Society of Anesthesiologists (ASA) classification ≥ 3 Neurological, orthopedic or rheumatologic injury or illness affecting physical ability Preoperatively known hernia requiring surgical operation Severe mental illness

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Study patients<br>Obese subjects scheduled to undergo abdominoplasty surgery are included. These are later classified according to metabolic status. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Inflammatory status | The inflammatory status will be studied in obese patients. | 2025 |
Total-Body Parametric 18F-FDG PET of COVID-19

Study Overview
=================
Brief Summary
-----------------
The primary objective is to measure the change between COVID-19 patients and normal subjects; the secondary objective is to measure the change in COVID-19 patients between baseline and 4-month follow up.

Official Title
-----------------
Total-Body Parametric 18F-FDG PET of COVID-19

Conditions
-----------------
Covid19

Intervention / Treatment
-----------------
* Device: uEXPLORER/mCT


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: COVID-19 positive patients will have a previous positive COVID-19 test and radiographic findings, and/or a positive SARS-CoV-2 antibody test and be in early recovery. First PET/CT visit needs to be within 8 weeks of COVID-19 diagnosis. Ability to understand and willingness to sign an informed consent form. Ability to adhere to the study visit schedule and other protocol requirements. All persons ≥18 years of age. Exclusion Criteria: Pregnant or lactating women. Any condition that would prohibit the understanding or rendering of informed consent. Unable to lie supine for 1-hour imaging with PET. Prisoners. Any comorbidity that, in the opinion of the investigator, could compromise protocol objectives.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: COVID-19 patients<br> | Device: uEXPLORER/mCT<br>* Each participant will undergo two 18F-FDG PET/CT scans, one at baseline and one at 4- month (+/- 2 weeks) follow-up.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| BAB permeability assessed | Evaluating if there is a change in BAB permeability assessed by lung FDG K1 for patients with COVID 19 | 1 imaging visit up to 60 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 4 month follow-up PET/CT scan | Evaluate the change in the scans between baseline scan and 4-month follow-up scan by assessing the pulmonary blood-air barrier permeability to glucose | 1 imaging visit up to 60 minutes |
A Genomic Analysis of Evolution of Epithelia Ovarian Tumors

Study Overview
=================
Brief Summary
-----------------
Epithelial ovarian carcinomatous and borderline components sometimes appeared in one patient. This study aims to analyze the genomic patterns of the carcinomatous and borderline components in the ovarian epithelial tissues. These tissues will be collected from paraffin section by microdissection to distinguish normal, carcinomatous and borderline tissues.

Official Title
-----------------
A Genomic Analysis on the Evolution of Epithelia Ovarian Tumors

Conditions
-----------------
Epithelial Ovarian Cancer, Epithelial Ovarian Tumor of Borderline Malignancy, Driving Mutations, Progression-free Survival

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Confirmed primary epithelial ovarian borderline tumor with cancer Signed an approved informed consents Feasible for sampling Exclusion Criteria: Not meeting all of the inclusion criteria
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Frequencies of somatic driving mutations | The differences of frequencies of somatic driving mutations will be compared between normal, carcinomatous and borderline tissues. | Two years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression-free survival | Progression-free survival between patients with differential expressed multi-omics will be compared. | Five years |
Maturity and Motor Fitness

Study Overview
=================
Brief Summary
-----------------
The current study examined the effect of maturity on the sprint and jump performances in a single year age group of 13 year old boys.

Detailed Description
-----------------
The investigators examined the issue in adolescent boys (n = 107) aged from 13.0 to 13.9 years. The maturity status was assessed using a self-assessment of stage of pubic hair based on the criteria of Tanner. Body composition and maximal voluntary knee extension torque (KET) were determined using a bioelectrical impedance analyzer and a static myometer, respectively. Sprint velocity was measured by a non-motorized treadmill. Jump height was calculated from the following equation; g × (flight time)2 × 8 × 10-1. The flight time during jumping was measured by a matswitch system.

Official Title
-----------------
EFFECT OF MATURITY ON SPRINT AND JUMP PERFORMANCES IN ADOLESCENT BOYS.

Conditions
-----------------
Physical Fitness

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adolescents Exclusion Criteria: subjects had some diseases and disorders

Ages Eligible for Study
-----------------
Minimum Age: 156 Months
Maximum Age: 167 Months

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Junior high school student<br>All subjects participated in measurements of body composition, muscle strength and motor fitness | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Body composition | Bioelectrical impedence - percent body fat | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Muscle strength | myometer- knee extension strength | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pubic hair, sprint velocity, vertical jump height, body composition, maximal voluntary torque